Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge - CNBC
- Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge CNBC
- Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand WSJ
- Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast qz.com
- Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress Eli Lilly and Company
- Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong Reuters
Related Markets
All MarketsMarket data may be delayed. Not financial advice.
💡 AI analysis provides alternative perspectives on current events